Patents by Inventor Laurent Knerr

Laurent Knerr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES
    Publication number: 20240101549
    Abstract: Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein X1, R1, R2, R3, R4, R5 and R6 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.
    Type: Application
    Filed: December 16, 2021
    Publication date: March 28, 2024
    Inventors: Jonas BRÅNALT, Björn HOLM, Maria JOHANSSON, Olle KARLSSON, Daniel Laurent KNERR, Anneli NORDQVIST, Robert John SHEPPARD, Marianne SWANSON, Anna TOMBERG
  • N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES
    Publication number: 20230312550
    Abstract: Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein X1, R1, R2, R3, R4, R5 and R6 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.
    Type: Application
    Filed: June 12, 2023
    Publication date: October 5, 2023
    Inventors: Jonas BRÅNALT, Björn HOLM, Maria JOHANSSON, Olle KARLSSON, Daniel Laurent KNERR, Anneli NORDQVIST, Robert John SHEPPARD, Marianne SWANSON, Anna TOMBERG
  • GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof
    Publication number: 20210346509
    Abstract: The present embodiments provide compounds and methods for targeting cells expressing GLP-1 receptor.
    Type: Application
    Filed: April 15, 2021
    Publication date: November 11, 2021
    Inventors: Brett P. Monia, Thazha P. Prakash, Garth A. KINBERGER, Richard Lee, Punit P. Seth, Shalini Andersson, Eva Carina Ämmälä, Daniel Laurent Knerr, Maria Astrid Ölwegård-Halvarsson, Eric Valeur, William John Drury, III
  • GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF
    Publication number: 20200268898
    Abstract: The present embodiments provide compounds and methods for targeting cells expressing GLP-1 receptor.
    Type: Application
    Filed: November 7, 2018
    Publication date: August 27, 2020
    Inventors: Brett P. MONIA, Thazha P. PRAKASH, Garth A. KINBERGER, Richard LEE, Punit P. SETH, Michael OESTERGAARD, Mehran NIKAN, Shalini ANDERSSON, Eva Carina AMMALA, Daniel Laurent KNERR, Maria OLWEGARD-HALVARSSON, William John DRURY, III, Eric VALEUR
  • GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof
    Publication number: 20190134214
    Abstract: The present embodiments provide compounds and methods for targeting cells expressing GLP-1 receptor.
    Type: Application
    Filed: May 4, 2017
    Publication date: May 9, 2019
    Inventors: Brett P. Monia, Thazha P. Prakash, Garth A. KINBERGER, Richard Lee, Punit P. Seth, Shalini Andersson, Eva Carina Ämmälä, Daniel Laurent Knerr, Maria Astrid Ölwegård-Halvarsson, Eric Valeur, William John Drury III
  • 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS
    Publication number: 20100105681
    Abstract: The present invention concerns 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
    Type: Application
    Filed: October 23, 2009
    Publication date: April 29, 2010
    Inventors: Marie-Agnes Lassoie, Laurent Knerr, Thierry Demaude, Françoise De Laveleye-Defais, Thierry Kogej, Luc Quere, Sylvain Routier, Gerald Guillaumet
  • 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as VLA-4 inhibitors
    Patent number: 7638630
    Abstract: The present invention concerns 2,6-quinolinyl and 2,6-naphthyl derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals for the treatment of VLA-4 dependent inflammatory diseases such as for example asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, psoriasis, urticaria, pruritus, eczema, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and atherosclerosis. Formula (I): wherein X is N or CH.
    Type: Grant
    Filed: April 15, 2003
    Date of Patent: December 29, 2009
    Assignee: UCB Pharma S.A.
    Inventors: Marie-Agnès Lassoie, Laurent Knerr, Thierry Demaude, Françoise De Laveleye-Defais, Thierry Kogej, Luc Quere, Sylvain Routier, Gerald Guillaumet
  • 2,6-Quinolinyl And 2,6-Naphthyl Derivatives, Processes For Preparing Them And Their Uses As Vla-4 Inhibitors
    Publication number: 20080064720
    Abstract: The present invention concerns 2,6-quinolinyl and 2,6-naphthyl derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals for the treatment of VLA-4 dependent inflammatory diseases such as for example asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, psoriasis, urticaria, pruritus, eczema, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and atherosclerosis. Formula (I): wherein X is N or CH.
    Type: Application
    Filed: April 15, 2003
    Publication date: March 13, 2008
    Applicant: UCB, S.A.
    Inventors: Marie-Agnes Lassoie, Laurent Knerr, Theirry Demaude, Francoise De Laveleye-Defais, Thierry Kogej, Luc Quere, Sylvain Routier, Gerald Guillaumet
  • Pyrrolidinone derivatives
    Patent number: 6936633
    Abstract: The present invention provides pharmaceutical compositions and novel compounds useful in the treatment of conditions mediated by CCR2, MCP-1 or the interaction thereof. The compounds of the present invention are pyrrolidinones and pyrrolidine-thiones.
    Type: Grant
    Filed: December 31, 2003
    Date of Patent: August 30, 2005
    Assignee: UCB S.A.
    Inventors: Dong Zou, Olivier Dasse, Janelle Evans, Paul Higgins, Jeremy Kintigh, Rama Kondru, Eric Schwartz, Laurent Knerr, Hai-Xiao Zhai
  • Pyrrolidinone derivatives
    Publication number: 20050004180
    Abstract: The present invention provides pharmaceutical compositions and novel compounds useful in the treatment of conditions mediated by CCR2, MCP-1 or the interaction thereof. The compounds of the present invention are pyrrolidinones and pyrrolidine-thiones.
    Type: Application
    Filed: September 26, 2002
    Publication date: January 6, 2005
    Inventors: Dong Zou, Olivier Dasse, Janelle Evans, Paul Higgins, Jeremy Kintigh, Laurent Knerr, Rama Kondru, Eric Schwartz, Hai-Xiao Zhai
  • Pyrrolidinone derivatives
    Publication number: 20040157914
    Abstract: The present invention provides pharmaceutical compositions and novel compounds useful in the treatment of conditions mediated by CCR2, MCP-1 or the interaction thereof. The compounds of the present invention are pyrrolidinones and pyrrolidine-thiones.
    Type: Application
    Filed: December 31, 2003
    Publication date: August 12, 2004
    Applicant: UCB, S.A.
    Inventors: Dong Zou, Olivier Dasse, Janelle Evans, Paul Higgins, Jeremy Kintigh, Rama Kondru, Eric Schwartz, Laurent Knerr, Hai-Xiao Zhai
  • Pyrrolidinone derivatives
    Patent number: 6727275
    Abstract: The present invention provides pharmaceutical compositions and novel compounds useful in the treatment of conditions mediated by CCR2, MCP-1 or the interaction thereof. The compounds of the present invention are pyrrolidinones and pyrrolidine-thiones.
    Type: Grant
    Filed: September 26, 2002
    Date of Patent: April 27, 2004
    Assignee: UCB, S.A./N.V.
    Inventors: Dong Zou, Olivier Dasse, Janelle Evans, Paul Higgins, Jeremy Kintigh, Rama Kondru, Eric Schwartz, Laurent Knerr, Hai-Xiao Zhai
  • Pyrrolidinone derivatives
    Publication number: 20030149081
    Abstract: The present invention provides pharmaceutical compositions and novel compounds useful in the treatment of conditions mediated by CCR2, MCP-1 or the interaction thereof. The compounds of the present invention are pyrrolidinones and pyrrolidine-thiones.
    Type: Application
    Filed: September 26, 2002
    Publication date: August 7, 2003
    Inventors: Dong Zou, Olivier Dasse, Janelle Evans, Paul Higgins, Jeremy Kintigh, Rama Kondru, Eric Schwartz, Laurent Knerr, Hai-Xiao Zhai